Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rapt Therapeutics Inc (RAPT)

Rapt Therapeutics Inc (RAPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,576
  • Shares Outstanding, K 34,903
  • Annual Sales, $ 0 K
  • Annual Income, $ -116,800 K
  • 60-Month Beta 0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.81
Trade RAPT with:

Options Overview Details

View History
  • Implied Volatility 251.31% ( -13.35%)
  • Historical Volatility 67.09%
  • IV Percentile 95%
  • IV Rank 56.95%
  • IV High 395.14% on 07/01/24
  • IV Low 61.03% on 02/01/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 237
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 21,988
  • Open Int (30-Day) 23,019

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.74
  • Number of Estimates 4
  • High Estimate -0.66
  • Low Estimate -0.79
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -12.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +27.97%
on 07/05/24
3.83 -12.68%
on 07/16/24
+0.29 (+9.51%)
since 06/26/24
3-Month
2.61 +27.97%
on 07/05/24
8.58 -61.07%
on 05/03/24
-4.76 (-58.77%)
since 04/26/24
52-Week
2.61 +27.97%
on 07/05/24
27.35 -87.79%
on 02/12/24
-20.68 (-86.09%)
since 07/26/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...

RAPT : 3.34 (+7.05%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...

RAPT : 3.34 (+7.05%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics Reports Second Quarter 2022 Financial Results

Company maintains strong cash position of $207.3 million...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics Reports First Quarter 2022 Financial Results

Company maintains strong cash position of $173.0 million...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

Company maintains strong cash position of $189.7 million...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...

RAPT : 3.34 (+7.05%)
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...

RAPT : 3.34 (+7.05%)

Business Summary

RAPT Therapeutics Inc. is a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for oncology and inflammatory diseases. The company's drug candidate consists of FLX475 for the treatment of tumors and RPT193,...

See More

Key Turning Points

3rd Resistance Point 3.59
2nd Resistance Point 3.47
1st Resistance Point 3.41
Last Price 3.34
1st Support Level 3.23
2nd Support Level 3.11
3rd Support Level 3.05

See More

52-Week High 27.35
Fibonacci 61.8% 17.90
Fibonacci 50% 14.98
Fibonacci 38.2% 12.06
Last Price 3.34
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar